Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke by.

Slides:

Advertisements

Similar presentations

Brain Single-Photon Emission CT With HMPAO and Safety of Thrombolytic Therapy in Acute Ischemic Stroke Proceedings of the Meeting of the SPECT Safe Thrombolysis.

Advertisements

Seeing a Stroke Developed by: K. Banasky, RN, BSN Educator GCH Emergency Services.

FERNE/MEMC Session: Treating Ischemic Stroke in the 3 – 4

Consultant Neurologist,

10 May 2005 CASES - Original article available at CASES (Canadian Alteplase for Stroke Effectiveness Study) The CASES Investigators.

Recognition and Treatment of Large MCA Strokes Matthew S. Smith, MD, MS Director of Neurocritical Care Assistant Professor of Neurology Assistant Professor.

Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Mechanical Thrombectomy for Acute Ischemic Stroke:

Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Elevated Plasma Levels of Neuropeptide Proenkephalin.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Non–ST-Segment Elevation Acute Coronary.

Admission Glucose and Mortality in Elderly Patients Hospitalized With Acute Myocardial Infarction by Mikhail Kosiborod, Saif S. Rathore, Silvio E. Inzucchi,

From: Risks of Cardiovascular Adverse Events and Death in Patients with Previous Stroke Undergoing Emergency Noncardiac, Nonintracranial Surgery:The Importance.

Copyright © 2010 American Medical Association. All rights reserved.

by J. Masjuan, M. Barón, M. Lousa, and J. M. Gobernado

Volume 28, Issue 6, Pages (December 2012)

Diffusion-Weighted MRI in Acute Subcortical Infarction

Comparison of Triflusal and Aspirin for Prevention of Vascular Events in Patients After Cerebral Infarction by Jordi Matías-Guiu, José M. Ferro, José Alvarez-Sabín,

Circ Cardiovasc Interv

12/15-Lipoxygenase Inhibition or Knockout Reduces Warfarin-Associated Hemorrhagic Transformation After Experimental Stroke by Yu Liu, Yi Zheng, Hulya Karatas,

Predictors of Good Outcome After Stent-Retriever Thrombectomy in Acute Basilar Artery Occlusion by Woong Yoon, Seul Kee Kim, Tae Wook Heo, Byung Hyun Baek,

Complications and Pitfalls in Rat Stroke Models for Middle Cerebral Artery Occlusion by Tibo Gerriets, Erwin Stolz, Maureen Walberer, Clemens Müller, Carina.

Noninvasive Quantification of Brain Edema and the Space-Occupying Effect in Rat Stroke Models Using Magnetic Resonance Imaging by T. Gerriets, E. Stolz,

Oxygen Therapy in Ischemic Stroke

Functional Recovery in Aged and Young Rats After Embolic Stroke

Prestroke Glycemic Control Is Associated With the Functional Outcome in Acute Ischemic Stroke by Masahiro Kamouchi, Takayuki Matsuki, Jun Hata, Takahiro.

by Holly Deng, Hyung Soo Han, Danye Cheng, Guo Hua Sun, and Midori A

Intracellular Action of Matrix Metalloproteinase-2 Accounts for Acute Myocardial Ischemia and Reperfusion Injury by Wenjie Wang, Costas J. Schulze, Wilma.

Risk of Recurrent Stroke in Patients With Silent Brain Infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) Imaging Substudy.

Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.

Behavior and Biology: The Basic Sciences for AHA Action

by Thomas Monks, Martin Pitt, Ken Stein, and Martin James

Relative Distributions

Neuroprotective Effect of Darbepoetin Alfa, a Novel Recombinant Erythropoietic Protein, in Focal Cerebral Ischemia in Rats by Ludmila Belayev, Larissa.

Contribution of Stroke to the Cochrane Stroke Group Trials Register

Iatrogenic Adverse Events in the Coronary Care Unit

Virtual Reality in Stroke Rehabilitation

Statin Treatment and Functional Outcome After Ischemic Stroke

by Jonathan G. Zaroff, Guy A. Rordorf, James S. Titus, John B

by Beverly G. Windham, Michael E

Circ Cardiovasc Qual Outcomes

Reflux Esophagitis and the Risk of Stroke in Young Adults

by Anuj Shah, Anand Shewale, Corey J. Hayes, and Bradley C. Martin

Multiparametric MRI Tissue Characterization in Clinical Stroke With Correlation to Clinical Outcome by Michael A. Jacobs, Panayiotis Mitsias, Hamid Soltanian-Zadeh,

Gene Transfer of Hepatocyte Growth Factor Gene Improves Learning and Memory in the Chronic Stage of Cerebral Infarction by Munehisa Shimamura, Naoyuki.

by Amy Kuceyeski, Hooman Kamel, Babak B

Circ Cardiovasc Qual Outcomes

Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.

by Manuel Yepes, Maria Sandkvist, Mike K. K. Wong, Timothy A

Clinical Policy: Use of Intravenous tPA for the Management of Acute Ischemic Stroke in the Emergency Department Annals of Emergency Medicine Volume.

Volume 14, Issue 5, Pages (May 2015)

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease Nina Raju, MD, MsC, Magdalena Sobieraj-Teague, MBBS, Jack Hirsh, MD,

Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Gregory Piazza et al. JCIN 2015;8:

Volume 14, Issue 5, Pages (May 2015)

Dandan Wang et al. BTS 2018;3: Overexpression of miR-24 Ameliorates Diabetic Ischemia/Reperfusion Injury (A) Schematic protocol of miR-24 delivery.

Dennis G. Moledina, MD, Mark A. Perazella, MD

Jennifer E. Fugate, DO, Alejandro A. Rabinstein, MD

A, A 50-year old female patient with acute ischemic stroke (AIS), visible as an area of reduced diffusion (dark region) on the apparent diffusion coefficient.

Figure 2 Kaplan-Meier survival graphs for 10-year risks of overall and post-90-day recurrent ischemic stroke (IS) and death Kaplan-Meier survival graphs.

Figure 1 Stacked bar chart depicts the proportion of patients with diffusion-weighted imaging (DWI)+ and DWI− scans categorized by index event type TIA.

Figure 1 Annualized percentage brain volume change

Figure 2 BVL according to on-study disability worsening

An example of the predicted risk of final infarct for 2 patients with acute ischemic stroke using 2 neural networks trained, respectively, on patients.

An example of the predicted risk of final infarct for 2 patients with acute ischemic stroke using 2 neural networks trained, respectively, on patients.

Preoperative Thienopyridine Use and Outcomes after Surgery: A Systematic Review Anita G. Au, MD, Sumit R. Majumdar, MD MPH, Finlay A. McAlister, MD MSc

Presentation transcript:

Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke by Mar Hernandez-Guillamon, Lidia Garcia-Bonilla, Montse Solé, Victoria Sosti, Mireia Parés, Mireia Campos, Arantxa Ortega-Aznar, Carmen Domínguez, Marta Rubiera, Marc Ribó, Manolo Quintana, Carlos A. Molina, José Alvarez-Sabín, Anna Rosell, Mercedes Unzeta, and Joan Montaner Stroke Volume 41(7):1528-1535 July 1, 2010 Copyright © American Heart Association, Inc. All rights reserved.

Figure I. VAP-1/SSAO activity in healthy controls (n=30) and stroke patients (n=140) upon arrival to the emergency department (within 3 h). Figure I. VAP-1/SSAO activity in healthy controls (n=30) and stroke patients (n=140) upon arrival to the emergency department (within 3 h). Mar Hernandez-Guillamon et al. Stroke. 2010;41:1528-1535 Copyright © American Heart Association, Inc. All rights reserved.

Figure 1. A, VAP-1/SSAO activity according to the presence of HT (B) and main HT subtypes of patterns. Figure 1. A, VAP-1/SSAO activity according to the presence of HT (B) and main HT subtypes of patterns. C, Baseline VAP-1/SSAO activity relates to all CT-based HT subtypes. Broken line indicates the reference interval for healthy controls. Mar Hernandez-Guillamon et al. Stroke. 2010;41:1528-1535 Copyright © American Heart Association, Inc. All rights reserved.

Figure 2. Plasma VAP-1/SSAO activity temporal profile according to HT presence or absence after stroke. Figure 2. Plasma VAP-1/SSAO activity temporal profile according to HT presence or absence after stroke. Broken line indicates the reference interval for healthy controls. Mar Hernandez-Guillamon et al. Stroke. 2010;41:1528-1535 Copyright © American Heart Association, Inc. All rights reserved.

Figure 3. Neurological outcome was determined in the acute phase (48 hours). Figure 3. Neurological outcome was determined in the acute phase (48 hours). Broken line indicates the reference interval for healthy controls. Mar Hernandez-Guillamon et al. Stroke. 2010;41:1528-1535 Copyright © American Heart Association, Inc. All rights reserved.

Figure 4. Representative brain VAP-1/SSAO immunostaining of a patient with stroke who had an HT; infarcted areas (A, C) compared with the corresponding contralateral (B; A–B bars=50 μm; C bar=10 μm). Figure 4. Representative brain VAP-1/SSAO immunostaining of a patient with stroke who had an HT; infarcted areas (A, C) compared with the corresponding contralateral (B; A–B bars=50 μm; C bar=10 μm). D, VAP-1/SSAO activity in infarcted areas (I) of human brain homogenates compared with contralateral areas (CL) or healthy control subjects. Mar Hernandez-Guillamon et al. Stroke. 2010;41:1528-1535 Copyright © American Heart Association, Inc. All rights reserved.

Figure II. Plasma VAP-1/SSAO activity of ischemic rats treated with delayed-tPA and saline or semicarbazide. Figure II. Plasma VAP-1/SSAO activity of ischemic rats treated with delayed-tPA and saline or semicarbazide. Mar Hernandez-Guillamon et al. Stroke. 2010;41:1528-1535 Copyright © American Heart Association, Inc. All rights reserved.

Figure 5. A, Infarct volume of rats treated with tPA at 2, 3, or 4 hours after clot embolism. Figure 5. A, Infarct volume of rats treated with tPA at 2, 3, or 4 hours after clot embolism. B, Infarct volume of ischemic rats cotreated with delayed tPA and either saline or semicarbazide. C, Representative images of 2–3-5-triphenyl tetrazolium chloride staining, (D) mortality rate, and (E) systemic bleeding. Mar Hernandez-Guillamon et al. Stroke. 2010;41:1528-1535 Copyright © American Heart Association, Inc. All rights reserved.